PerkinElmer Inc
LSE:0KHE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
PerkinElmer Inc
EPS (Diluted)
PerkinElmer Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
PerkinElmer Inc
LSE:0KHE
|
EPS (Diluted)
$2
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
1%
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
EPS (Diluted)
$17
|
CAGR 3-Years
0%
|
CAGR 5-Years
2%
|
CAGR 10-Years
14%
|
|
|
Danaher Corp
NYSE:DHR
|
EPS (Diluted)
$5
|
CAGR 3-Years
-19%
|
CAGR 5-Years
1%
|
CAGR 10-Years
1%
|
|
|
Waters Corp
NYSE:WAT
|
EPS (Diluted)
$10
|
CAGR 3-Years
-3%
|
CAGR 5-Years
5%
|
CAGR 10-Years
7%
|
|
|
Agilent Technologies Inc
NYSE:A
|
EPS (Diluted)
$4
|
CAGR 3-Years
1%
|
CAGR 5-Years
12%
|
CAGR 10-Years
12%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
EPS (Diluted)
$7
|
CAGR 3-Years
11%
|
CAGR 5-Years
41%
|
CAGR 10-Years
10%
|
|
PerkinElmer Inc
Glance View
PerkinElmer Inc., originally founded in 1937, has evolved over the decades into a leading global innovator in the field of healthcare and life sciences. It began its journey by focusing on precision optics, but with time, the company strategically pivoted towards life sciences, diagnostics, and applied markets. This transformation harnessed its focus on innovative technologies that aid in the process of scientific discovery and clinical diagnostics. PerkinElmer primarily thrives on providing advanced solutions for detecting and analyzing biological and chemical compounds. With its robust portfolio of products and services, the company empowers laboratories and research institutions worldwide to unlock new insights into areas such as genetics, oncology, and environmental health. The company's revenue streams are multifaceted, embodying a mix of instruments, software, and services that cater to a variety of needs in the scientific and healthcare communities. PerkinElmer’s business model is anchored on selling sophisticated laboratory equipment like mass spectrometers, imaging systems, and diagnostic testing kits. Beyond equipment sales, the company also capitalizes on recurring revenue from consumables and services, ensuring a steady cash flow that supports its ongoing R&D efforts and market expansion initiatives. Furthermore, with a strategic emphasis on bolstering partnerships and acquisitions, PerkinElmer continually enhances its capability to deliver comprehensive solutions, thus maintaining its competitive edge in the ever-evolving scientific landscape. Through this, it manages to contribute not just to profitability but to a broader mission of improving global health outcomes.
See Also
What is PerkinElmer Inc's EPS (Diluted)?
EPS (Diluted)
2.1
USD
Based on the financial report for Dec 28, 2025, PerkinElmer Inc's EPS (Diluted) amounts to 2.1 USD.
What is PerkinElmer Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
1%
Over the last year, the EPS (Diluted) growth was -6%. The average annual EPS (Diluted) growth rates for PerkinElmer Inc have been -23% over the past three years , -21% over the past five years , and 1% over the past ten years .